Stock Details
DSKYF is Daiichi Sankyo Company, Limited's stock. Stock exchange Other OTC (Currency USD). Average price in 50 days is 24.99$. Average daily volumn in 3 months 5.3k. Market cap 49.68B



Stock symbol : DSKYF. Exchange : Other OTC. Currency : USD
Lastest price : 25.92$. Total volume : 694.00. Market state PRE
Click reload if you want to check the lastest price on market!!!

Daiichi Sankyo Company, Limited (DSKYF)
Last Price
25.92$
Change
0.22
Volume
694.00

Previous Close25.70
Open25.41
Day Range25.41-25.92
Bid0.00 x N/A
Ask0.00 x N/A
Volume694
Average Volume5.3k
Market Cap49.68B
Beta0.72
52 Week Range17.61-28.93
Trailing P/E99.69
Foward P/E68.21
Dividend (Yield %)0.82%
Ex-Dividend Date2022-09-29



Financial Details


According to Daiichi Sankyo Company, Limited's financial reports the company's revenue in 2022 were 1.04T an decrease( +3.95%) over the years 2021 revenue that were of 962.52B. In 2022 the company's total earnings were 66.97B while total earnings in 2021 were 75.96B(-12%).


Loading ...



Organization

Daiichi Sankyo Company, Limited researches and develops, manufactures, imports, markets, and sells pharmaceutical products worldwide. The company offers trastuzumab deruxtecan, an anti-cancer agent and anti-HER2 antibody drug conjugate; mirogabalin for pain treatment; teneligliptin/canagliflozin for type 2 diabetes mellitus treatment; lacosamide anti-epileptic agent; prasugrel, an antiplatelet agent; denosumab for osteoporosis and bone disorders; teneligliptin for type 2 diabetes mellitus treatm... ent; edoxaban, an anticoagulant; esomeprazole for ulcer treatment; memantine for treating Alzheimer's disease; and laninamivir for anti-influenza treatment. It also provides olmesartan, an antihypertensive agent; levofloxacin, an antibacterial agent; pravastatin for hypercholesterolemia treatment; and loxoprofen, an anti-inflammatory analgesic. In addition, the company offers colesevelam for treating hypercholesterolemia and type 2 diabetes mellitus treatment; and ferric carboxymaltose and iron sucrose injections for treating anemia. Further, it provides Lulu, a combination cold remedy; Loxonin S, an antipyretic analgesic /anti-inflammatory analgesic; Transino for melasma improvement and treating against spots and freckles; Minon, a skincare product; and Breath Labo and Clean Dental oral care products, as well as Silodosin for dysuria; Gefitinib for malignant tumours; Bicalutamide for prostate cancer; and Tamoxifen, an anti-breast cancer agent. Additionally, the company offers adsorbed cell culture-derived influenza, influenza HA, measles rubella combined, and mumps vaccines. It also provides pharmaceuticals and drugs for animals, cosmetics, medical equipment, food products, drinking water, active pharmaceutical ingredients, and intermediates. It has collaboration with Guardant Health to develop Guardant360 CDx as a companion diagnostic for Enhertu in advanced metastatic non-small cell lung cancer. The company was founded in 1899 and is headquartered in Tokyo, Japan.

Market Cap:
49.68B
Revenue:
1.04T
Total Assets:
2.22T
Total Cash:
662.48B


News about "Daiichi Sankyo Company, Limited"

Daiichi Sankyo Co. Ltd. ADR

Source from : Wall Street Journal - 12 days ago

1 Day DSNKY 2.65% DJIA 2.68% S&P 500 3.06% Health Care/Life Sciences -1.01% Sunao Manabe President, CEO & Representative Director Daiichi Sankyo Co., Ltd. Hiroyuki Okuzawa CFO, Director ...See details»


Daiichi Sankyo Company, Limited (OTCMKTS:DSNKY) Sees Significant Drop in Short Interest

Source from : ETF Daily News - 20 days ago

Daiichi Sankyo Company, Limited (OTCMKTS:DSNKY โ€“ Get Rating Daiichi Sankyo stock opened at $23.06 on Friday. The company has a 50 day moving average price of $24.87 and a 200-day moving average ...See details»


DSNKY Daiichi Sankyo Company, Limited

Source from : Seeking Alpha - 6 days ago

The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.See details»


Daiichi Sankyo Co Ltd - Stock Quote DSKYF

Source from : Morningstar%2c Inc. - 8 days ago

There is no one analyst in which a Quantitative Star Rating and Fair Value Estimate is attributed to; however, Mr. Lee Davidson, Head of Quantitative Research for Morningstar, Inc., is responsible ...See details»


Daiichi Sankyo submits sNDA to Japanโ€™s MHLW for trastuzumab deruxtecan to treat patients with HER2 low metastatic breast cancer

Source from : Pharmabiz - 9 days ago

Daiichi Sankyo submits sNDA to Japanโ€™s MHLW for trastuzumab deruxtecan to treat patients with HER2 low metastatic breast cancer: Tokyo Tuesday, June 28, 2022, 16:00 Hrs [IST] Da ...See details»


video-symptom-management-is-critical-for-treatment-continuation-in-prostate-cancer-image

VIDEO: Symptom management is โ€˜criticalโ€™ for treatment continuation in prostate cancer

Source from : Healio - 1 days ago

Healio spoke with Daniel P. Petrylak, MD, about a presentation the American Urological Association meeting that focused on discontinuation rates of hormone therapy options among patients with advanced ...See details»


Alzheimerโ€™s Drugs Market Future Business Growth 2022-2028 | AstraZeneca, Daiichi Sankyo Company Limited, H. Lundbeck A/S, Novartis AG

Source from : Digital Journal - 10 days ago

and the actual process. Alzheimerโ€™s Drugs Market reports cover complete modest view with the market stake and company profiles of the important contestants working in the worldwide market.See details»


AstraZeneca to make 90 million COVID-19 doses in Japan

Source from : ๆœๆ—ฅๆ–ฐ่ž็คพ - 11 days ago

The drug company turned to local production to ensure ... will produce the content of the vaccine, while Tokyo-based Daiichi Sankyo Co. and KM Biologics Co., based in Kumamoto Prefecture, will ...See details»


Daiichi Sankyo doses first person in breast cancer treatment trial

Source from : London South East - 24 days ago

(Alliance News) - Daiichi Sankyo Co Ltd on Monday said it dosed the first patient in the Tropion-Breast02 phase three trial, evaluating the safety and efficacy of datopotamab deruxtecan in ...See details»


For treatment of some breast cancers, 2 drugs approved by European Union

Source from : Mint - 10 days ago

Global pharma company AstraZeneca said June 27 that its cancer drugs Lynparza, developed with Merck & Co and Enhertu, developed with Japan's Daiichi Sankyo, were recommended for the treatment of ...See details»


exelixis-to-webcast-fireside-chat-as-part-of-the-william-blair-biotech-focus-conference-image

Exelixis to Webcast Fireside Chat as Part of the William Blair Biotech Focus Conference

Source from : YAHOO!Finance - 1 days ago

Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in a pre-recorded fireside chat at the William Blair Biotech Focus Conference 2022, which will be available to ...See details»


roquefort-therapeutics-buys-uk-biotech-in-return-for-shares-image

Roquefort Therapeutics buys UK biotech in return for shares

Source from : the Top 10 - 14 days ago

Medical biotechnology company, Roquefort Therapeutics, has conditionally agreed to buy UK biotech Oncogeni Ltd in return for shares.See details»


TROPION-Breast02 Phase 3 Trial of Datopotamab Deruxtecan Initiated in Patients with Previously Untreated Metastatic Triple Negative Breast Cancer

Source from : Yahoo Finance - 24 days ago

About the Daiichi Sankyo and AstraZeneca Collaboration Daiichi Sankyo Company, Limited (referred to as Daiichi Sankyo) and AstraZeneca entered into a global collaboration to jointly develop and ...See details»


Rohde & Schwarz opens subsidiary in Israel

Source from : Na Presseportal - 6 days ago

The establishment of an Israeli subsidiary is now the next logical step for the company. Frank Oehler, Managing Director of Rohde & Schwarz Israel Ltd., explains: โ€œWorking directly with our ...See details»